From left: U.S. Congressman Pete Olson; Ann Tanabe, CEO of BioHouston; Young Park, CEO of GeneOne Life Science; Jim Greenwood, President of BIO; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO of THBI.
VGXI was honored to host U.S. Congressman Pete Olson and several key industry leaders for a roundtable discussion on the state of biotech and innovation in Texas. Attendees included President of the Biotechnology Innovation Organization (BIO), Jim Greenwood, as well as Tom Kowalski, President of the Texas Healthcare and Bioscience Institute, and Ann Tanabe, CEO of BioHouston. The visitors toured VGXI’s state-of-the-art cGMP plasmid DNA manufacturing facility and met with the CEO of VGXI and GeneOne Life Science, Young Park. The roundtable discussion that followed focused on funding and policy issues facing the biotech community, and the important role of innovative companies like VGXI.
VGXI is the only facility in the world to have manufactured DNA vaccines for Ebola, MERS, and Zika. In July of 2016 VGXI’s parent company GeneOne Life Science announced the start of a Phase-1 trial to evaluate the Zika DNA vaccine (GLS-5700), which has been demonstrated in animal models to provide 100% protection from the virus. This trial set a record as one of the fastest development timelines from initial concept of the vaccine to FDA approval for human testing.
Roundtable attendees noted the exceptional safety profile and rapid manufacturing timeline for DNA vaccines, making them a smarter and more cost effective approach to emerging diseases. “Establishing commercial scale manufacturing capability for plasmid DNA within the US will ensure we are ready to support production and widespread distribution of these vaccines in response to future outbreaks,” stated GeneOne CEO Young Park.
ABOUT VGXI, INC.
With over 15 years of experience, VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research. The company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for clinical trials in the US, EU, Asia and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CMO of GeneOne Life Science, Inc.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for preclinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world.
Biotechnology Innovation Organization (BIO) is the world’s largest trade association representing nearly 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
Texas Healthcare and Bioscience Institute is the Texas Policy voice for healthcare and bioscience and the only provider of statewide resources to our members and the industry. With a focus on using advocacy as a tool to create a more favorable environment for the life sciences, THBI works with government and industry leaders to attract new participants in the life sciences to Texas and to promote effective government legislation on behalf of the industry.
BioHouston, Inc. is a non-profit corporation founded by Houston area academic/research institutions, leading a broad effort to establish the Houston region as a vigorous global competitor in life science and biotechnology commercialization. Our mission is to create an environment that will stimulate technology transfer and research commercialization, thereby generating economic wealth for the Houston region and making it a global competitor in life science commercialization. BioHouston’s activities provide the greatest leverage in making the Houston region a world-class competitor in the life science industry.
Cautionary Factors That May Affect Future Results
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
Christy Franco, PhD
Business Development Manager